Indonesia Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031)

The Indonesian Continuous Glucose Monitoring (CGM) Market is set to reach USD 4.6 Million in 2031, growing at a CAGR of 17.2% from USD 2.1 Million in 2026.

The CGM market in Indonesia in 2025 was influenced by the high volume of diabetes in Indonesia and the ongoing government efforts to manage the burden of non-communicable diseases (NCD) through the Ministry of Health. The Ministry of Health's own statistics for Indonesia show that there is a high prevalence of diabetes in the country, but that a great deal of this population is undiagnosed, hence a substantial gap in early detection and an ongoing process for managing the diabetes population. As a result, the Indonesian government has increased nationwide public health screening programs through Puskesmas and expanded its activities for early detection of high-risk diabetes patients in the context of its 2025 public health objectives.

• BPJS Kesehatan (JKN), Indonesia's national insurance plan, has also developed plans and pathways for structured diabetes care as part of the public healthcare facilities, and thus continues to improve access to the routine monitoring and also the services needed for managing chronic illnesses.

• Due to the high cost and inadequate infrastructure available for CGM to date, it is still at a relatively early stage of development and use in Indonesia. However, the adoption of CGM continues to improve in the country as a result of the government's continued commitment to early detection, long-term management of diabetes and expansion of screening programs through the primary health care system.

• Indonesia’s CGM market in 2025 is driven by a rapidly expanding diabetes burden among adults aged 20–79 years, rising from 5.7 million in 2000 to 7.3 million in 2011 and 20.4 million in 2024, with projections reaching 28.6 million by 2050.

• This trajectory places Indonesia among the highest-burden diabetes countries globally, as reflected in internationally used public health datasets integrated into national planning frameworks. The increasing prevalence is structurally linked to underdiagnosis, with a large proportion of cases remaining undetected in routine screening systems.

• In response, Indonesia’s health system is intensifying Puskesmas-based screening and chronic disease management under BPJS Kesehatan. CGM adoption remains concentrated in tertiary urban care, but rising case volume and complexity are pushing a gradual clinical shift toward continuous monitoring over episodic glucose testing.

Java is the fastest-growing region in this market, driven by rising diabetes prevalence and rapidly expanding healthcare infrastructure investments.

• The Java region is expected to grow in this market, driven by high population density, rising diabetes prevalence, better hospital access, and strong healthcare infrastructure in major urban centres.

• The sensors segment is expected to grow due to increasing demand for accurate real-time glucose tracking and rising adoption of wearable monitoring technologies.

• Real-time CGM is expected to grow due to preference for instant glucose alerts, improved patient monitoring, and growing smartphone-based diabetes management.

• The Type 1 diabetes application is expected to grow due to rising diagnosis rates and higher dependence on continuous monitoring for precise insulin management.

• The hospitals’ end-user segment is expected to grow due to increasing patient inflow, advanced diagnostic adoption, and availability of specialised diabetes care services.

Market Dynamics

Drivers

Rising Diabetes Prevalence

The growing number of people with diabetes is one of the main factors driving Indonesia’s Continuous Glucose Monitoring (CGM) market. This increase is further driven by rapid urbanization, changing food habits, and a more sedentary lifestyle. Indonesia is one of the nations with a large and increasing diabetic population, and a considerable number of cases are left undiagnosed or poorly managed, leading to the patients being at a higher risk of having serious complications such as heart disease, kidney failure, and nerve damage.

• The number of people living with diabetes in Indonesia is growing quickly among adults aged 20 to 79 years.

• It is estimated to rise from about 20.4 million in 2024 to as many as 28.6 million by 2050.

• This large increase points to a growing problem of diabetes in the country and shows the importance of introducing modern monitoring devices like Continuous Glucose Monitoring (CGM) systems to help patients manage their condition over time and lower the risk of complications.

• Besides, raising awareness regarding the importance of early diagnosis and continuous monitoring, with the support of programs like Gerakan Masyarakat Hidup Sehat (GERMAS), motivates both patients and doctors to use the latest diabetes management devices.

• Daewoong Pharmaceutical declared in December 2025 that it had officially received the marketing approval from Indonesia's National Agency of Drug and Food Control (BPOM) for its new diabetes medication, Enavogliflozin.

Market Segmentation

By End-User: Hospitals

The Indonesian continuous glucose monitoring (CGM) market, segmented by end user, is mainly led by hospitals, home care settings, and diabetes clinics, each playing a distinct role in the adoption and use of these products. Hospitals hold a large part of the market because they have sophisticated infrastructure, healthcare professionals with proper training, and the capacity to handle complicated diabetes cases that require continuous monitoring and immediate intervention. The hospitals are expected to show considerable growth, mainly due to the availability of highly developed healthcare infrastructure, excellent medical personnel, and the large number of patients needing comprehensive diabetes management.

• Hospitals usually serve as the main point of care for patients with uncontrolled or complicated diabetes conditions, where CGM is crucial for real-time glucose level measurement and timely clinical decision-making.

• The use of CGM devices in hospitals is also encouraged by the rising prevalence of diabetes in Indonesia, which has resulted in healthcare professionals looking for more accurate and data-oriented patient monitoring tools.

• Besides, hospitals are also the major promoters for the adoption of CGM devices as far as technological innovations are concerned. Nearly 63% of the total 3, 016 hospitals in Indonesia are privately owned.

• Their utilization in hospital admissions, intensive care units (ICUs), and perioperative management is aimed at not only enhancing patient outcomes but also at minimizing diabetes-related complications such as hypoglycemia and hyperglycemia.

• Government initiatives support the adoption of continuous glucose monitoring (CGM) in the hospital segment of Indonesia. Indonesia’s healthcare strategy is targeting 90% diabetes control among the affected population by 2029.

• One such program is the national health insurance program (JKN) initiated by BPJS Kesehatan, which broadens access to services for diabetes care.

• The other programs, like the Indonesia Health Transformation Program and Gerakan Masyarakat Hidup Sehat (GERMAS) or the Healthy Living Community Movement, also contribute to the development of healthcare infrastructure, public awareness, and early diagnosis.

• These activities make the use of advanced monitoring technologies such as CGMs in hospitals more likely.

Regional Analysis

Java (Jakarta, West Java, Central Java, East Java)

By region, the Indonesian Continuous Glucose Monitoring (CGM) market is segmented into Java (Jakarta, West Java, Central Java, East Java), Sumatra, Kalimantan, Sulawesi, Bali & Nusa Tenggara, and Papua. Among these, Java dominates the market due to its high population density, well-established healthcare infrastructure, and greater awareness regarding advanced diabetes management solutions.

Meanwhile, regions such as Sumatra and Sulawesi are witnessing steady growth driven by improving healthcare access and rising diabetes prevalence. Kalimantan, Bali & Nusa Tenggara, and Papua are emerging markets with gradual adoption, supported by ongoing healthcare development initiatives and increasing awareness of continuous glucose monitoring technologies. The Java region is expected to grow significantly, driven by the high prevalence of diabetes, increasing urbanization, and strong access to advanced healthcare infrastructure. The concentration of hospitals, diagnostic centers, and endocrinology specialists in major cities such as Jakarta and Surabaya is accelerating the adoption of continuous glucose monitoring (CGM) devices.

• The rising prevalence of diabetes and lifestyle-related disorders, estimated at around ~11% of the adult population in Indonesia in 2025, coupled with the high population density and urbanization across Java (Jakarta, West Java, Central Java, and East Java), is significantly driving demand for CGM devices in the region.

• Increasing urban population is supporting higher adoption of advanced healthcare technologies, including CGM devices, particularly in metropolitan regions such as Jakarta and West Java. Based on Indonesia's Statistics Agency (BPS) and government-related studies, Java is the most urbanized and densely populated island in Indonesia, holding over 60% of the total population.

• Growing awareness regarding real-time glucose monitoring and better disease management is encouraging patients to shift from traditional blood glucose monitoring methods to CGM systems.

• Expansion of private hospitals, specialty clinics, and diagnostic centers is improving accessibility to advanced diabetes care solutions across the region.

• Increasing inclination toward preventive healthcare and continuous monitoring is driving demand for wearable and connected health devices.

• Integration of digital health technologies, including mobile apps and remote monitoring systems, is enhancing patient engagement and supporting CGM adoption.

• Favorable government initiatives and improving insurance coverage for chronic disease management are further contributing to market growth in Java.

• For instance, Indonesia’s national health insurance program, BPJS Kesehatan, has expanded coverage for diabetes diagnosis and treatment, enabling wider patient access to monitoring and care services, thereby supporting the adoption of advanced solutions such as CGM devices.

• Continuous product innovation, including minimally invasive and user-friendly CGM devices, is attracting both patients and healthcare providers, accelerating market expansion. For example, devices such as FreeStyle Libre and Dexcom G6 offer factory-calibrated sensors, real-time glucose tracking, and smartphone integration, significantly improving convenience and encouraging wider adoption among users.

List of Companies

• Abbott Laboratories

• Dexcom, Inc.

• Medtronic plc

• Sinocare Inc.

• Roche Diabetes Care GmbH

• Ascensia Diabetes Care Holdings AG

Abbott Laboratories is an American-based company that specializes in healthcare and medical devices. The company operates its business worldwide by providing diagnostic services, medical equipment, nutritional products, and branded generic pharmaceuticals to customers in more than 160 nations. The company has received wide recognition for its development of innovative solutions that treat chronic diseases, especially in diabetes management, cardiovascular device development, and rapid diagnostic testing. Abbott uses its digital health technology to create medical devices that help patients achieve better health results, and its ongoing work in CGM systems and connected care platforms demonstrates this approach.

Through its FreeStyle Libre product line, Abbott has created a successful international business that is one of the most commonly used CGM systems worldwide, including in Indonesia. Abbott operates its business in Indonesia through its official local business, PT Abbott Products Indonesia, which has its main office in Jakarta. The FreeStyle Libre product range offers all Abbott continuous glucose monitoring devices used in Indonesia, including the FreeStyle Libre series and its newer versions. These products include factory-calibrated sensors that enable smartphone connectivity and continuous data monitoring to function as budget-friendly substitutes for traditional continuous glucose monitoring devices.

Indonesia Continuous Glucose Monitoring (CGM) Market Scope